Clinical Trials on Unexplained Hypophosphatemia in Japan

Total 50 results

Kyowa Kirin Co., Ltd.

Active, not recruiting

Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners (SUNFLOWER)

X-Linked Hypophosphatemia

Japan
Zeria Pharmaceutical

Completed

Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets

Primary Hypophosphatemic Rickets

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia

X-linked Hypophosphatemic Rickets/Osteomalacia

Japan, Korea, Republic of
Kyowa Kirin Co., Ltd.

Completed

A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia

X-linked Hypophosphatemic Rickets/Osteomalacia

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia

XLH

Japan, Korea, Republic of
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)

X-Linked Hypophosphatemia

Korea, Republic of, Canada, United States, Australia, Japan, United Kingdom, Sweden
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

United States, Korea, Republic of, Japan, Ireland, United Kingdom, France, Italy
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

United States, Korea, Republic of, Canada, Japan, France, Denmark
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia Patients on Hemodialysis

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Hemodialysis Patients With Hyperphosphatemia

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD

Hyperphosphatemia

Japan
Bayer

Completed

Bioequivalence Study of BAY77-1931 Granule

Hyperphosphatemia

Japan
Kyowa Kirin Co., Ltd.

Completed

Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients

Hyperphosphatemia

Japan
Kyowa Kirin Co., Ltd.

Completed

Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia

Japan
Bayer

Completed

Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan (FOSRENOL-CAPD)

Hyperphosphatemia

Japan
Kyowa Kirin Co., Ltd.

Completed

Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis

Hyperphosphatemia

Japan
Kyowa Kirin Co., Ltd.

Completed

Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia

Japan
Kyowa Kirin Co., Ltd.

Completed

Dose-finding Study of KHK7791 in Hyperphosphatemia Patients

Hyperphosphatemia

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Hemodialysis | Hyperphosphatemia

Japan
Kyowa Kirin Co., Ltd.

Completed

Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia

Japan
Bayer

Completed

Fosrenol Post-marketing Surveillance for Hemodialysis in Japan (FOSRENOL-HD)

Hyperphosphatemia

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia

Hemodialysis | Hyperphosphatemia

Japan
Bayer

Completed

Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone

Hyperphosphatemia | Dialysis

Japan
Astellas Pharma Inc

Completed

Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan

Chronic Kidney Disease | Hyperphosphatemia Undergoing Hemodialysis

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

Peritoneal Dialysis | Hyperphosphatemia

Japan
Astellas Pharma Inc

Completed

Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

Japan
Bayer

Completed

Fosrenol Post-marketing Surveillance in Japan

Hyperphosphatemia | Kidney Disease

Japan
Translational Research Center for Medical Innovation...
Showa University School of Medicine

Completed

Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study (LANDMARK)

Hemodialysis | Hyperphosphatemia

Japan
Bayer

Completed

BAY 77-1931 Long-term Extension From Phase II Study

Hyperphosphatemia

Japan
Astellas Pharma Inc

Completed

A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis

Renal Insufficiency | Chronic Kidney Disease | Renal Dialysis

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia

Chronic Kidney Disease Requiring Hemodialysis

Japan
Astellas Pharma Inc

Completed

Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

Renal Insufficiency | Chronic Kidney Disease | Hyperphosphatemia | Renal Dialysis

Japan
Bayer

Completed

Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients

Hyperphosphatemia

Japan
Astellas Pharma Inc

Completed

A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

Renal Insufficiency | Chronic Kidney Disease | Renal Dialysis

Japan
Astellas Pharma Inc

Completed

Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Renal Insufficiency | Chronic Kidney Disease | Hyperphosphatemia

Japan
Astellas Pharma Inc

Completed

A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Renal Insufficiency | Chronic Kidney Disease | Hyperphosphatemia

Japan
Astellas Pharma Inc

Completed

A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

Chronic Kidney Disease | Hyperphosphatemia

Japan
Bayer

Completed

Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants

Overactive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic Cough

Japan
Osaka University
Bayer

Enrolling by invitation

Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia (LAVALIER)

Renal Insufficiency, Chronic | Bone Diseases, Metabolic | Hyperphosphatemia

Japan
Astellas Pharma Inc

Completed

Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis

Chronic Renal Failure

Japan
KDL Inc.

Completed

A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

Chronic Kidney Disease | Hyperphosphatemia

Japan
Astellas Pharma Inc

Completed

Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients

Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis

Japan
Bayer

Completed

Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate

Hyperphosphatemia

Japan
Translational Research Center for Medical Innovation...
Osaka University Graduate School of Medicine

Completed

Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)

Hypophosphatasia

Japan
Bayer
Shire

Completed

Study in Chronic Kidney Disease (CKD) Not on Dialysis

Hyperphosphatemia

Japan
Alexion Pharmaceuticals

Completed

Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

Hypophosphatasia

United States, Spain, Australia, United Kingdom, Italy, France, Canada, Germany, Japan, Russian Federation, Saudi Arabia, Turkey
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa (CHESTNUT)

Hypophosphatasia

Australia, United States, Japan, Germany, Turkey, Italy, India, France, United Kingdom, Argentina, Canada
Bayer
Shire

Completed

Long-term Study in Chronic Kidney Disease (Extension From Study 14817)

Hyperphosphatemia

Japan
Bayer

Completed

Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough (PAGANINI)

Refractory and/or Unexplained Chronic Cough

Belgium, Taiwan, Australia, Netherlands, Spain, Japan, United States, Germany, Turkey, United Kingdom, Argentina, Italy, Slovakia, Hungary, France, Canada, Czechia, Poland, Russian Federation
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa (HICKORY)

Hypophosphatasia

Italy, Spain, Israel, Korea, Republic of, Belgium, Germany, United States, China, France, Taiwan, Austria, Japan, India, Australia, Argentina, Poland, Turkey, Brazil, Canada, Thailand, United Kingdom, Slovakia, Czechia

Clinical Trials on Unexplained Hypophosphatemia in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations